Safety, tolerability, and antibody response of active A beta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Background Immunotherapy targeting the amyloid beta (A beta) peptide is a potential strategy to slow the progression of Alzheimer's disease. We aimed to assess the safety and tolerability of CAD106, a novel active A beta immunotherapy for patients with Alzheimer's disease, designed to induce N-terminal A beta-specific antibodies without an A beta-specific T-cell response. Methods We did a phase 1,